论文部分内容阅读
肿瘤细胞抗原肽SLIVHLNEV可以与MHC-I类分子结合,由T细胞表位识别,激活细胞毒性T细胞(CTL),为肝癌免疫治疗开辟了新领域。文章通过软件DNAstar-protean与Syfpeithi分析,确定抗原肽的抗原表位。然后抗原肽刺激树突细胞,通过检测CD80,CD86的表达,观察抗原肽诱导树突细胞成熟的情况。将负载抗原肽的树突细胞与T细胞的混合淋巴细胞反应(MLR),MTT检测T细胞增殖的情况,确定最佳抗原肽浓度与最佳刺效比。以最佳抗原肽浓度与最佳刺效比刺激T淋巴细胞分化,测定T细胞表面CD8、CD4表达情况。结果表明抗原肽SLIVHLNEV不含B淋巴细胞抗原表位,而为HLA_A*02∶01型T淋巴细胞表位抗原,并可以刺激H2-Db表位,经树突细胞(APC)递呈,刺激T细胞分化为CTL,发挥细胞免疫作用。
The tumor cell antigen peptide SLIVHLNEV can bind to MHC class I molecules and recognize T cell epitopes to activate cytotoxic T lymphocytes (CTLs), opening up a new field for the immunotherapy of liver cancer. The article through the software DNAstar-protean and Syfpeithi analysis to determine the antigenic peptide epitopes. The antigen peptide then stimulated dendritic cells, and the expression of CD80 and CD86 was detected to observe the antigenic peptide-induced dendritic cell maturation. Mixed lymphocyte reaction (MLR) of dendritic cells loaded with antigen peptides with T cells was performed to detect the proliferation of T cells. MTT assay was used to determine the best antigen peptide concentration and the best thrombocytopenic ratio. T lymphocyte differentiation was stimulated with the best antigen peptide concentration and the best thrombocytopenic purpura, and the expression of CD8 and CD4 on T cells was measured. The results showed that the antigen peptide SLIVHLNEV does not contain B lymphocyte epitopes, but HLA-A * 02:01 T lymphocyte epitope antigen, and can stimulate H2-Db epitopes, presented by dendritic cells (APC), stimulate T Cells differentiate into CTLs and exert cellular immunity.